Compare Hudbay Minerals Inc. Ordinary Shares (Canada) (HBM) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hudbay Minerals Inc. Ordinary Shares (Canada) vs Hinge Health Inc. Class A Common Stock — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $23.45 (market cap $11.37B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hudbay Minerals Inc. Ordinary Shares (Canada) is the larger of the two by market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 6 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| HBM | HNGE | |
|---|---|---|
Market Cap | $11.37B | $8.48B |
Volume | 3,520,423 | 879,799 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $105.14 |
52-Week Low | $14.58 | $31.17 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.43B | $8.10B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HudBay Minerals (HBM) trades at $25.68, down 0.31% with bearish technical signals despite solid fundamentals. The company reported strong 2025 results with $2.21B revenue and $568.5M net income, while analyst consensus remains positive with 60% buy ratings. Recent news highlights HBM4 equipment delays and copper/gold reserve expansions at Snow Lake operations.
HBM presents a value opportunity with reasonable valuation (P/E 15.77) and strong profitability (ROE 18.43%), though technical weakness and HBM market dynamics pose near-term risks. The stock's outlook depends on execution of copper growth strategy and resolution of memory sector supply chain concerns.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hudbay Minerals Inc. Ordinary Shares (Canada)
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
